This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.
Researchers from the Cleveland Clinic have conducted the first human trials of a new drug, lepodisiran, that has the potential to eliminate a risk factor for cardiovascular disease for which there is currently no treatment.
Gene therapy has restored partial hearing in four out of five deaf children in a Shanghai trial, with each child regaining roughly 60 to 65 percent of typical hearing ability. The Fudan University team used a harmless virus to ferry a working copy of the otoferlin gene directly into the inner ear, where it began producing the protein these children had been missing since birth. Most had heard little or nothing their whole lives, so even partial hearing opens a window for spoken language to develop during early childhood. Parallel trials at Cambridge and Regeneron suggest the field is converging on a shared approach — a hopeful proof of concept that could one day extend to many more forms of inherited deafness.
Dubbed “Calixcoca,” the treatment, developed by researchers at the Federal University of Minas Gerais, triggers an immune response that blocks cocaine and crack from reaching the brain. Last week, the project won the top prize of €500,000 at the Euro Health Innovation Awards for Latin American medicine.
The researchers from the University of Cambridge found that, on its own, the blood test could diagnose up to 30% of patients with BD, but combining it with the online psychiatric assessment significantly improved the diagnosis rate, especially in people whose diagnosis was not obvious.
High-speed rail just arrived in the Southern Hemisphere for the first time, with Indonesia’s new Jakarta–Bandung line cutting a three-hour trip down to 46 minutes. Trains glide along the 142-kilometer route at around 350 km/h, linking two cities home to nearly 14 million people on one of the most densely populated islands on Earth. Plans are already in motion to extend the corridor to Surabaya, which could turn an eight-hour journey across Java into a two- or three-hour ride. Beyond the convenience, electrified rail is the cleanest way to move people long distances, and tends to pull travelers off short-haul flights. For the wider Global South, it’s a hopeful sign that world-class low-carbon transport isn’t reserved for wealthier corners of the map.
Cervical cancer survival rates could improve dramatically after a major clinical trial found that adding a short course of chemotherapy before standard treatment reduces the risk of death or recurrence by 35%. Led by University College London researchers and funded by Cancer Research U.K., the trial showed 80% of women using the new approach were alive at five years, compared to 72% receiving standard treatment alone. The finding is considered the biggest advance in cervical cancer outcomes in over 20 years. Crucially, the drugs involved are already approved, widely available, and inexpensive, meaning the protocol could be adopted globally without new approvals or manufacturing delays.
Researchers at Sweden’s Chalmers University of Technology have developed an incredibly efficient way to recycle metals from spent batteries, and at the same time minimize the loss of valuable raw materials such as nickel, cobalt and manganese. No expensive or harmful chemicals are required in the process.
Bioprinted skin combining all six primary skin cell types has, for the first time, been successfully grafted onto wounds in pre-clinical trials — closing them faster and with noticeably less scarring. Researchers at Wake Forest layered keratinocytes, fibroblasts, adipocytes, melanocytes, and two other cell types into a three-layer structure mirroring real skin, then watched it grow blood vessels and integrate naturally with surrounding tissue. A larger graft, roughly two inches square, worked on a pig model — a meaningful step toward the kind of scale human patients actually need. For burn survivors and others who simply don’t have enough healthy skin to donate, a lab-grown alternative made from their own cells could transform one of medicine’s most painful, limited tools into something closer to true regeneration.
The R21/Matrix-M vaccine, developed at Oxford University, is expected to offer countries a cheaper and more readily available option than the world’s first shot against the parasitic disease.
Researchers at the University of North Carolina have developed an AI model that can predict in real-time whether or not cancerous tissue has been fully removed during breast cancer surgery. The model performed as well as, or better than, human doctors.
